News

News 09.03.2023 Zurich-Schlieren, Switzerland, March 9, 2023. Proteomedix, a Swiss diagnostics company committed to advance prostate cancer care, today announced that new results evaluating Proclarix® in combination with imaging were published in BJU International[1]. The early detection of clinically significant prostate cancer decreases prostate cancer mortality. The use of multiparametric magnetic resonance imaging...

Events, Internal events
Event date: 07.03.2023 7th of March, 16.15-17.00 Auditorium Bio Technopark Schlieren, Wagistrasse 25, 8952 Schlieren Are you working in biotech and love to hear about exciting science, discuss innovative ideas and learn about struggles and creative solutions? So do we! Engaging discussions and collaborations are invaluable for productive science, innovation and for creating new, disruptive ideas. This...

News 28.02.2023 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced the presentation of new preclinical data from the...

News 21.02.2023 Schlieren (Zurich), Switzerland, 21 February, 2023 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, today announced the publication of key scientific data on the efficacy of MagnetOs bone graft in two prestigious, peer-reviewed scientific journals. Joost de Bruijn, Chief Executive Officer of Kuros, said:...

News 20.01.2023 Paul Bravetti (Brenus CEO) about this collaboration : “Despite advances in therapy, a significant number of cancers remain resistant to treatment because the cancer cells can adapt and become invisible to the immune system, causing the patient to relapse. These cold tumors, which escape the immune cells and become for the...